Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2007

View Archived Issues

Recent patents disclose novel antidiabetic agents

Recent patents claim novel agents for obesity and metabolic disorders

Amgen identifies new CXCR3 antagonists with potential in autoimmune disorders

First patient enrolled in Akela Pharma phase IIb CGRP trial in asthma

Medivir recovers MIV-210 licensing rights and partners with Noken

Rivaroxaban prevents venous thromboembolism in hip replacement setting

Peplin completes Australasian actinic keratosis trial enrollment

New therapeutic agents for cancer covered in recent patent literature

Boehringer Ingelheim offers Apotex nevirapine license in developing countries

DMC recommends continuation of Isotechnika's phase IIb kidney transplant trial

Almirall completes acquisition of Hermal

ExonHit and Allergan's EHT/AGN-001 to begin phase I trials

Novel c-Met inhibitors described by Pfizer

Antisense inhibition of the growth hormone receptor effective in a model of retinopathy in vivo

Vical initiates phase I trial of Vaxfectin-formulated pDNA influenza vaccine

Access licenses MuGuard to SpePharm in Europe

FDA approves multiple day dosing of MGI Pharma and Helsinn's Aloxi injection

Quark extends siRNA compound research agreement with SUNY Buffalo

Nexavar sNDA granted FDA priority review for liver cancer indication

Positive results for Bayer and Onyx's Asia-Pacific phase III trial of Nexavar

Jerini regains North American marketing rights to icatibant in hereditary angioedema

Positive results from second phase III clinical trial of NeurogesX's dermal patch in PHN

Cubicin expanded indication approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...